Progress in the development of PET radiotracers has enabled the noninvasive assessment of the pathological hallmarks of Alzheimer disease (AD) and other neurodegenerative disorders. New reports have revealed the potential usefulness of tau PET imaging in AD and non-AD tauopathies.
References
Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239–259 (1991).
Crary, J. F. et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 128, 755–766 (2014).
Villemagne, V. L. et al. Tau imaging: early progress and future directions. Lancet Neurol. 14, 114–124 (2015).
Pontecorvo, M. J. et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain 140, 748–763 (2017).
Murray, M. E. et al. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 10, 785–796 (2011).
Ossenkoppele, R. et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain 139, 1551–1567 (2016).
Lowe, V. J. et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol. Commun. 4, 58 (2016).
Passamonti, L. et al. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Brain 140, 781–791 (2017).
Kikuchi, A. et al. In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET. Neurology 87, 2309–2316 (2016).
Giacobini, E. & Gold, G. Alzheimer disease therapy — moving from amyloid-β to tau. Nat. Rev. Neurol. 9, 677–686 (2013).
Acknowledgements
The authors would like to thank R. Harada for substantial contributions to the discussion of content for this article. This study was supported by Grant-in-Aid for Scientific Research (B) (15H04900) and Grant-in-Aid for Scientific Research on Innovative Areas (Brain Protein Aging and Dementia Control) (26117003) from MEXT, Japan.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
N.O. is a consultant for CLINO and has received royalties from GE Healthcare.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Okamura, N., Yanai, K. Applications of tau PET imaging. Nat Rev Neurol 13, 197–198 (2017). https://doi.org/10.1038/nrneurol.2017.38
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2017.38
- Springer Nature Limited
This article is cited by
-
Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update
Journal of Biomedical Science (2023)
-
Stacked binding of a PET ligand to Alzheimer’s tau paired helical filaments
Nature Communications (2023)
-
Clinical trials of new drugs for Alzheimer disease
Journal of Biomedical Science (2020)
-
Direct attenuation correction of brain PET images using only emission data via a deep convolutional encoder-decoder (Deep-DAC)
European Radiology (2019)
-
PET imaging of tau protein targets: a methodology perspective
Brain Imaging and Behavior (2019)